Does the media prefer BCRX or HALO?

In the previous week, Halozyme Therapeutics had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 12 mentions for Halozyme Therapeutics and 9 mentions for BioCryst Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 1.28 beat BioCryst Pharmaceuticals' score of 1.16 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 8 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALKS or BCRX?

In the previous week, Alkermes had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 10 mentions for Alkermes and 9 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.16 beat Alkermes' score of 0.80 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BCRX or RGEN?

In the previous week, BioCryst Pharmaceuticals had 4 more articles in the media than Repligen. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 5 mentions for Repligen. Repligen's average media sentiment score of 1.56 beat BioCryst Pharmaceuticals' score of 1.16 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to LGND or BCRX?

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 12 mentions for Ligand Pharmaceuticals and 9 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.16 beat Ligand Pharmaceuticals' score of 0.97 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BCRX or CLDX?

In the previous week, BioCryst Pharmaceuticals had 5 more articles in the media than Celldex Therapeutics. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 4 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.62 beat BioCryst Pharmaceuticals' score of 1.16 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

BioCryst Pharmaceuticals (BCRX) Competitors

$9.91 -0.54 (-5.17%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$9.94 +0.03 (+0.29%)

As of 06:00 AM Eastern

Compare

BCRX vs. HALO, ALKS, RGEN, LGND, and CLDX

Should you buy BioCryst Pharmaceuticals stock or one of its competitors? MarketBeat compares BioCryst Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioCryst Pharmaceuticals include Halozyme Therapeutics (HALO), Alkermes (ALKS), Repligen (RGEN), Ligand Pharmaceuticals (LGND), and Celldex Therapeutics (CLDX). These companies are all part of the "biotechnology" industry.

How does BioCryst Pharmaceuticals compare to Halozyme Therapeutics?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

In the previous week, Halozyme Therapeutics had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 12 mentions for Halozyme Therapeutics and 9 mentions for BioCryst Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 1.28 beat BioCryst Pharmaceuticals' score of 1.16 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	8 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has a net margin of 23.13% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Halozyme Therapeutics' return on equity of 187.91% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Halozyme Therapeutics	23.13%	187.91%	21.92%

BioCryst Pharmaceuticals presently has a consensus target price of $20.80, suggesting a potential upside of 109.89%. Halozyme Therapeutics has a consensus target price of $81.60, suggesting a potential upside of 7.21%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe BioCryst Pharmaceuticals is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Halozyme Therapeutics has higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.88	$263.86M	-$1.78	N/A
Halozyme Therapeutics	$1.40B	6.46	$316.89M	$2.78	27.38

BioCryst Pharmaceuticals has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Summary

Halozyme Therapeutics beats BioCryst Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Alkermes?

Alkermes (NASDAQ:ALKS) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

Alkermes has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Alkermes has a net margin of 9.78% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Alkermes' return on equity of 9.26% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

Alkermes presently has a consensus price target of $51.25, suggesting a potential downside of 1.20%. BioCryst Pharmaceuticals has a consensus price target of $20.80, suggesting a potential upside of 109.89%. Given BioCryst Pharmaceuticals' higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

95.2% of Alkermes shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 4.6% of Alkermes shares are held by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Alkermes had 1 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 10 mentions for Alkermes and 9 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.16 beat Alkermes' score of 0.80 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioCryst Pharmaceuticals has lower revenue, but higher earnings than Alkermes. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	5.86	$241.66M	$0.90	57.63
BioCryst Pharmaceuticals	$874.84M	2.88	$263.86M	-$1.78	N/A

Summary

Alkermes beats BioCryst Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Repligen?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Repligen has a net margin of 6.73% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Repligen's return on equity of 4.88% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Repligen	6.73%	4.88%	3.48%

BioCryst Pharmaceuticals has higher revenue and earnings than Repligen. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.88	$263.86M	-$1.78	N/A
Repligen	$738.26M	11.07	$48.89M	$0.90	160.98

BioCryst Pharmaceuticals currently has a consensus target price of $20.80, suggesting a potential upside of 109.89%. Repligen has a consensus target price of $165.00, suggesting a potential upside of 13.89%. Given BioCryst Pharmaceuticals' higher probable upside, equities research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Repligen	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 0.6% of Repligen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, BioCryst Pharmaceuticals had 4 more articles in the media than Repligen. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 5 mentions for Repligen. Repligen's average media sentiment score of 1.56 beat BioCryst Pharmaceuticals' score of 1.16 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Repligen has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Summary

Repligen beats BioCryst Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 12 mentions for Ligand Pharmaceuticals and 9 mentions for BioCryst Pharmaceuticals. BioCryst Pharmaceuticals' average media sentiment score of 1.16 beat Ligand Pharmaceuticals' score of 0.97 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ligand Pharmaceuticals presently has a consensus price target of $292.86, suggesting a potential downside of 5.30%. BioCryst Pharmaceuticals has a consensus price target of $20.80, suggesting a potential upside of 109.89%. Given BioCryst Pharmaceuticals' higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

Ligand Pharmaceuticals has a net margin of 55.95% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Ligand Pharmaceuticals' return on equity of 16.19% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

BioCryst Pharmaceuticals has higher revenue and earnings than Ligand Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	23.12	$124.45M	$7.37	41.96
BioCryst Pharmaceuticals	$874.84M	2.88	$263.86M	-$1.78	N/A

Ligand Pharmaceuticals has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Summary

Ligand Pharmaceuticals beats BioCryst Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does BioCryst Pharmaceuticals compare to Celldex Therapeutics?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Celldex Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Celldex Therapeutics' return on equity of -50.72% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Celldex Therapeutics	N/A	-50.72%	-46.59%

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BioCryst Pharmaceuticals presently has a consensus target price of $20.80, suggesting a potential upside of 109.89%. Celldex Therapeutics has a consensus target price of $49.30, suggesting a potential upside of 27.95%. Given BioCryst Pharmaceuticals' higher probable upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.88	$263.86M	-$1.78	N/A
Celldex Therapeutics	$1.54M	1,963.78	-$258.76M	-$4.26	N/A

In the previous week, BioCryst Pharmaceuticals had 5 more articles in the media than Celldex Therapeutics. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 4 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.62 beat BioCryst Pharmaceuticals' score of 1.16 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

BioCryst Pharmaceuticals and Celldex Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get BioCryst Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCRX vs. The Competition

Export

Metric	BioCryst Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.66B	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-5.57	19.17	27.11	24.26
Price / Sales	2.88	838.79	589.96	117.88
Price / Cash	8.44	56.80	29.22	49.36
Price / Book	-17.39	4.22	10.74	6.29
Net Income	$263.86M	$64.26M	$3.58B	$330.66M
7 Day Performance	-9.83%	-3.58%	-2.11%	-1.35%
1 Month Performance	13.91%	2.12%	3.27%	-0.64%
1 Year Performance	10.60%	20.35%	26.31%	19.08%

BioCryst Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCRX BioCryst Pharmaceuticals	3.1951 of 5 stars	$9.91 -5.2%	$20.80 +109.9%	+13.1%	$2.66B	$874.84M	N/A	530	Positive News Analyst Forecast Gap Down
HALO Halozyme Therapeutics	4.0764 of 5 stars	$80.78 +1.7%	$81.60 +1.0%	+33.2%	$9.42B	$1.40B	29.06	390	Positive News
ALKS Alkermes	1.746 of 5 stars	$55.14 +1.0%	$49.63 -10.0%	+71.3%	$9.10B	$1.48B	61.27	2,050	Analyst Forecast
RGEN Repligen	3.116 of 5 stars	$141.46 -0.7%	$163.57 +15.6%	+11.3%	$8.03B	$738.26M	157.18	2,000	Positive News
LGND Ligand Pharmaceuticals	2.7141 of 5 stars	$320.42 +0.3%	$257.71 -19.6%	+154.1%	$6.40B	$268.09M	43.48	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCRX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. HALO, ALKS, RGEN, LGND, and CLDX

How does BioCryst Pharmaceuticals compare to Halozyme Therapeutics?

Summary

How does BioCryst Pharmaceuticals compare to Alkermes?

Summary

How does BioCryst Pharmaceuticals compare to Repligen?

Summary

How does BioCryst Pharmaceuticals compare to Ligand Pharmaceuticals?

Summary

How does BioCryst Pharmaceuticals compare to Celldex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCryst Pharmaceuticals (BCRX) Competitors

BCRX vs. HALO, ALKS, RGEN, LGND, and CLDX

How does BioCryst Pharmaceuticals compare to Halozyme Therapeutics?

Does the media prefer BCRX or HALO?

Is BCRX or HALO more profitable?

Do analysts recommend BCRX or HALO?

Do institutionals and insiders hold more shares of BCRX or HALO?

Which has higher valuation and earnings, BCRX or HALO?

Which has more volatility and risk, BCRX or HALO?

Summary

How does BioCryst Pharmaceuticals compare to Alkermes?

Which has more volatility and risk, ALKS or BCRX?

Is ALKS or BCRX more profitable?

Do analysts rate ALKS or BCRX?

Do insiders and institutionals have more ownership in ALKS or BCRX?

Does the media refer more to ALKS or BCRX?

Which has higher earnings and valuation, ALKS or BCRX?

Summary

How does BioCryst Pharmaceuticals compare to Repligen?

Is BCRX or RGEN more profitable?

Which has preferable valuation and earnings, BCRX or RGEN?

Do analysts rate BCRX or RGEN?

Do insiders & institutionals hold more shares of BCRX or RGEN?

Does the media refer more to BCRX or RGEN?

Which has more risk & volatility, BCRX or RGEN?

Summary

How does BioCryst Pharmaceuticals compare to Ligand Pharmaceuticals?

Does the media refer more to LGND or BCRX?

Do insiders and institutionals have more ownership in LGND or BCRX?

Do analysts prefer LGND or BCRX?

Is LGND or BCRX more profitable?

Which has stronger valuation & earnings, LGND or BCRX?

Which has more risk & volatility, LGND or BCRX?

Summary

How does BioCryst Pharmaceuticals compare to Celldex Therapeutics?

Is BCRX or CLDX more profitable?

Do institutionals & insiders hold more shares of BCRX or CLDX?

Do analysts rate BCRX or CLDX?

Which has more volatility and risk, BCRX or CLDX?

Which has higher valuation & earnings, BCRX or CLDX?

Does the media prefer BCRX or CLDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCRX vs. The Competition

BioCryst Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools